Urelumab alone or in combination with rituximab in patients with relapsed or refractory B‐cell lymphoma
Urelumab, a fully human, non-ligand binding, CD137 agonist IgG4 monoclonal antibody, enhances T-cell and natural killer-cell antitumor activity in preclinical models, and may enhance cytotoxic activity of rituximab. Here we report results in patients with relapsed or refractory diffuse large B-cell...
Saved in:
| Main Authors: | , , , , , , , , , , , , , , , , , , , |
|---|---|
| 格式: | Artigo |
| 語言: | 英语 |
| 出版: |
2020
|
| 在線閱讀: | https://doi.org/10.1002/ajh.25757 https://onlinelibrary.wiley.com/doi/pdfdirect/10.1002/ajh.25757 |
| 標簽: |
添加標簽
沒有標簽, 成為第一個標記此記錄!
|